1-20 of 41
Edward Agura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MSc,MDFRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MDPhD, John M. Pagel, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-134624
Published: 2020
Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MSc,MDFRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Y. Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MDPhD, John M. Pagel, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-134948
Published: 2020
Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Patrick J. Stiff, MD, Edward Agura, MD, Mark Litzow, MD, Ben Tomlinson, MD, Hannah K. Choe, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, George L. Chen, MD, Parameswaran Hari, MBBS, MD, Zaid S. Al-Kadhimi, MD, James M. Foran, MD, Johnnie Orozco, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MD, Partow Kebriaei, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio A Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD DSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5642.
https://doi.org/10.1182/blood-2019-122776
Published: 2019
Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Clinical Trials & Observations Brief Report
Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham
Journal: Blood
Blood (2018) 132 (25): 2639–2642.
https://doi.org/10.1182/blood-2018-07-861641
Published: 2018
Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1017.
https://doi.org/10.1182/blood-2018-99-111914
Published: 2018
Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani
Journal: Blood
Blood (2018) 132 (1): 40–48.
https://doi.org/10.1182/blood-2017-11-815183
Published: 2018
Includes: Supplemental data
Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Hagop M. Kantarjian, MD, Kebede H. Begna, MD, Jessica K. Altman, MD, Stuart L. Goldberg, MD, Mikkael A. Sekeres, MD MS, Stephen A Strickland, Stephen E. Rubenstein, MD, Martha L. Arellano, MD, David F. Claxton, Maria R. Baer, MD, Marc Gautier, MD, Ellin Berman, MD, Karen Seiter, MD, Scott R Solomon, MD, Gary J. Schiller, MD, Selina Luger, MD FRCPC, Aleksandra Butrym, Gianluca Gaidano, MD PhD, Xavier Thomas, MD, Pau Montesinos, MD PhD, David A. Rizzieri, MD, Donald P. Quick, MD, Edward Agura, MD, Parameswaran Venugopal, MD, Janakiraman Subramanian, MD, Lori J. Maness, MD, Daniel-Eric Robert, MD, Yosr Hicheri, Tapan Kadia, MD, Farhad Ravandi, MBBS, Marc E. Buyse, ScD, Judy Chiao, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 891.
https://doi.org/10.1182/blood.V130.Suppl_1.891.891
Published: 2017
Journal Articles

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, MD, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, MD, Edward Agura, Jeffrey Matous, Stephen Ansell, MD PhD, Howland Crosswell, MD, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O'Connor, MD, Neil Josephson, Ranjana Advani
Journal: Blood
Blood (2015) 126 (23): 3982.
https://doi.org/10.1182/blood.V126.23.3982.3982
Published: 2015
Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 3172.
https://doi.org/10.1182/blood.V126.23.3172.3172
Published: 2015
Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD
Journal: Blood
Blood (2014) 124 (21): 293.
https://doi.org/10.1182/blood.V124.21.293.293
Published: 2014
Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski
Journal: Blood
Blood (2014) 124 (21): 673.
https://doi.org/10.1182/blood.V124.21.673.673
Published: 2014
Journal Articles

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Clinical Trials & Observations
Christopher Bredeson, Jennifer LeRademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie R. Tomblyn, Ginna G. Laport, Xiaochun Zhu, Philip L. McCarthy, Vincent T. Ho, Kenneth R. Cooke, Elizabeth Armstrong, Angela Smith, J. Douglas Rizzo, Jeanne M. Burkart, Marcelo C. Pasquini
Journal: Blood
Blood (2013) 122 (24): 3871–3878.
https://doi.org/10.1182/blood-2013-08-519009
Published: 2013
Includes: Supplemental data
Journal Articles

Differential Gene Expression Analysis Predicts For Response To Bortezomib In The Treatment Of Steroid Refractory Chronic Graft-Versus-Host Disease (cGVHD)

Alan M Miller, MD, PhD, Reva Schneider, MD, Estil A. Vance, MD, Edward Agura, MD, Sheila Powell, RN, Virginia Pascual, MD, Indira Munagala, Huanying Qin, MS
Journal: Blood
Blood (2013) 122 (21): 4587.
https://doi.org/10.1182/blood.V122.21.4587.4587
Published: 2013
Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Boglarka Gyurkocza, M.D., Rainer Storb, M.D., Barry E. Storer, Ph., D., Thomas Chauncey, MD, Thoralf Lange, M.D., Ginna G. Laport, MD, Amelia Langston, M.D., Michael A. Pulsipher, M.D., Christopher Bredeson, M.D., Richard Maziarz, M.D., Benedetto Bruno, M.D., Finn Petersen, M.D., Michael Maris, M.D., Edward Agura, M.D., Andrew M. Yeager, M.D., Wolfgang A. Bethge, M.D., Firoozeh Sahebi, M.D., Frederick R. Appelbaum, M.D., David G. Maloney, M.D., Elihu H. Estey, M.D., Brenda M. Sandmaier, MD
Journal: Blood
Blood (2010) 116 (21): 3450.
https://doi.org/10.1182/blood.V116.21.3450.3450
Published: 2010
Journal Articles

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Georg N. Franke, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Edward Agura, MD, Michael T. Maris, MD, James Wade, MD, Michael A. Pulsipher, MD, Richard T Maziarz, MD, Firoozeh Sahebi, MS, Peter McSweeney, MD, Benedetto Bruno, MD, Lars indelov, V, MD, Andrew M. Yeager, MD, Andrew Rezvani, MD, Dietger W Niederwieser, MD, Karl G. Blume, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1292.
https://doi.org/10.1182/blood.V116.21.1292.1292
Published: 2010
Journal Articles

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Leanthe Braunert, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Christopher Bredeson, Richard T Maziarz, MD, Michael A. Pulsipher, MD, Edward Agura, MD, Michael T. Maris, MD, Lars Vindelov, MD, Firoozeh Sahebi, M.D., Peter McSweeney, Benedetto Bruno, MD, Amelia Langston, MD, Rainer F. Storb, MD, David G. Maloney
Journal: Blood
Blood (2010) 116 (21): 2364.
https://doi.org/10.1182/blood.V116.21.2364.2364
Published: 2010
Journal Articles

Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS)

Mikkael A. Sekeres, MD, MS, Gail J. Roboz, MD, Olatoyosi Odenike, MD, Edward Agura, MD, Bayard L. Powell, MD, Reginald Ewesuedo, MD, Michael J. Vasconcelles, MD, Stefan Faderl, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2010) 116 (21): 1869.
https://doi.org/10.1182/blood.V116.21.1869.1869
Published: 2010
Journal Articles

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

Edward Agura, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Nikhil Munshi, MD, Mohamad Hussein, MD, Ramakrishnan V Parameswaran, MD, Stefano Tarantolo, MD, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Jeffrey A Zonder, MD
Journal: Blood
Blood (2009) 114 (22): 2870.
https://doi.org/10.1182/blood.V114.22.2870.2870
Published: 2009
Journal Articles

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry E Storer, Thoralf Lange, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Peter A. McSweeney, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick R Appelbaum, MD, William Bensinger, MD, Brenda M Sandmaier, MD, Rainer F Storb, George E. Georges, MD, David G Maloney, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3391.
https://doi.org/10.1182/blood.V114.22.3391.3391
Published: 2009
Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Edward Agura, MD, R. Brian Berryman, MD, Luis Pineiro, MD, Mirjana Tadic-Ovcina, Ryan Woelfel, Estil A. Vance, MD, Joseph W. Fay, MD
Journal: Blood
Blood (2008) 112 (11): 4320.
https://doi.org/10.1182/blood.V112.11.4320.4320
Published: 2008